Skip to content
The Policy VaultThe Policy Vault

Cometriq (cabozantinib) — Highmark

progressive, metastatic medullary thyroid cancer

Initial criteria

  • age ≥ 18 years
  • diagnosis of progressive, metastatic medullary thyroid cancer (ICD-10: C73)